The AGA Center for Gut MicrobiomeResearch and Education’s scientific advisory board recommended the papers and shared their thoughts.
Here are seven notable papers:
- Purna Kashyap recommended two studies: “A role for bacterial urease in guy dysbiosis and Crohn’s disease” and “Commensal bacteria make GPCR ligands that mimic human signalling molecules.“
The first study highlights the role of amino acids in dysbiosis and their association with disease severity, gut dysbiosis and bacterial production of amino acids in Crohn’s disease patients.
The second study provides a new paradigm and examples of how gut microbes affect host physiology through bacteria-encoded or bacteria-produced molecules acting on receptors.
- Geoffrey Preidis, MD, PhD, recommended, “The intestinal microbiota regulates body composition through NFIL3 and the circadian clock.” He said the article “advances our understanding of how gut microbes influence body composition.”
- Eugene Chang, MD, recommended two studies: “Diet-induced extinctions in the gut microbiota compound over generations,” and “Peripartum antibiotics promote gut dysbiosis, loss of immune tolerance, and inflammatory bowel disease in genetically prone offspring.” He said both studies address important inflammatory bowel disease issues.
- Jasmohan Bajaj, MD, recommended, “Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.” Dr. Bajaj said this was the first randomized controlled trial on fecal microbiota transplantation. Researchers treated hepatic encephalopathy by using FMT.
- Zain Kassam, MD, recommended, “The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection.” Dr. Kassam said the paper not only provides a framework to physicians for starting FMT, but it also shares solutions to manage patients with recurrent C. difficile infections.
To read the whole post, click here.
More articles on gastroenterology:
Exact Sciences, Takeda & more — 4 GI company key notes
C. diff market open to competition, analysts say — 3 insights
Irritable bowel syndrome risk higher for middle-aged adults — 4 insights
